Cargando…

Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma

Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamani-Ahmadmahmudi, Mohamad, Nassiri, Seyed Mahdi, Asadabadi, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548397/
https://www.ncbi.nlm.nih.gov/pubmed/34702929
http://dx.doi.org/10.1038/s41598-021-00746-0
_version_ 1784590564600053760
author Zamani-Ahmadmahmudi, Mohamad
Nassiri, Seyed Mahdi
Asadabadi, Amir
author_facet Zamani-Ahmadmahmudi, Mohamad
Nassiri, Seyed Mahdi
Asadabadi, Amir
author_sort Zamani-Ahmadmahmudi, Mohamad
collection PubMed
description Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene signatures for DLBCL have been recently developed. The major drawback of the previous signatures is their inability to correctly predict survival in external data sets. In other words, they are not reproducible in other datasets. Hence, in this study, we sought to determine the gene(s) that can reproducibly and robustly predict survival in patients with DLBCL. Gene expression data were extracted from 7 datasets containing 1636 patients (GSE10846 [n = 420], GSE31312 [n = 470], GSE11318 [n = 203], GSE32918 [n = 172], GSE4475 [n = 123], GSE69051 [n = 157], and GSE34171 [n = 91]). Genes significantly associated with overall survival were detected using the univariate Cox proportional hazards analysis with a P value < 0.001 and a false discovery rate (FDR) < 5%. Thereafter, significant genes common between all the datasets were extracted. Additionally, chromosomal aberrations in the corresponding region of the final common gene(s) were evaluated as copy number alterations using the single nucleotide polymorphism (SNP) data of 570 patients with DLBCL (GSE58718 [n = 242], GSE57277 [n = 148], and GSE34171 [n = 180]). Our results indicated that reticulon family gene 1 (RTN1) was the only gene that met our rigorous pipeline criteria and associated with a favorable clinical outcome in all the datasets (P < 0.001, FDR < 5%). In the multivariate Cox proportional hazards analysis, this gene remained independent of the routine international prognostic index components (i.e., age, stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group [ECOG] performance status, and number of extranodal sites) (P < 0.0001). Furthermore, no significant chromosomal aberration was found in the RTN1 genomic region (14q23.1: Start 59,595,976/End 59,870,966).
format Online
Article
Text
id pubmed-8548397
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85483972021-10-27 Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma Zamani-Ahmadmahmudi, Mohamad Nassiri, Seyed Mahdi Asadabadi, Amir Sci Rep Article Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene signatures for DLBCL have been recently developed. The major drawback of the previous signatures is their inability to correctly predict survival in external data sets. In other words, they are not reproducible in other datasets. Hence, in this study, we sought to determine the gene(s) that can reproducibly and robustly predict survival in patients with DLBCL. Gene expression data were extracted from 7 datasets containing 1636 patients (GSE10846 [n = 420], GSE31312 [n = 470], GSE11318 [n = 203], GSE32918 [n = 172], GSE4475 [n = 123], GSE69051 [n = 157], and GSE34171 [n = 91]). Genes significantly associated with overall survival were detected using the univariate Cox proportional hazards analysis with a P value < 0.001 and a false discovery rate (FDR) < 5%. Thereafter, significant genes common between all the datasets were extracted. Additionally, chromosomal aberrations in the corresponding region of the final common gene(s) were evaluated as copy number alterations using the single nucleotide polymorphism (SNP) data of 570 patients with DLBCL (GSE58718 [n = 242], GSE57277 [n = 148], and GSE34171 [n = 180]). Our results indicated that reticulon family gene 1 (RTN1) was the only gene that met our rigorous pipeline criteria and associated with a favorable clinical outcome in all the datasets (P < 0.001, FDR < 5%). In the multivariate Cox proportional hazards analysis, this gene remained independent of the routine international prognostic index components (i.e., age, stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group [ECOG] performance status, and number of extranodal sites) (P < 0.0001). Furthermore, no significant chromosomal aberration was found in the RTN1 genomic region (14q23.1: Start 59,595,976/End 59,870,966). Nature Publishing Group UK 2021-10-26 /pmc/articles/PMC8548397/ /pubmed/34702929 http://dx.doi.org/10.1038/s41598-021-00746-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zamani-Ahmadmahmudi, Mohamad
Nassiri, Seyed Mahdi
Asadabadi, Amir
Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title_full Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title_fullStr Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title_full_unstemmed Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title_short Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
title_sort prognostic efficacy of the rtn1 gene in patients with diffuse large b-cell lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548397/
https://www.ncbi.nlm.nih.gov/pubmed/34702929
http://dx.doi.org/10.1038/s41598-021-00746-0
work_keys_str_mv AT zamaniahmadmahmudimohamad prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma
AT nassiriseyedmahdi prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma
AT asadabadiamir prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma